or Try an Advanced Search...

    Novartis Stocks List

    Symbol Grade Name % Change
    XOMA A XOMA Corporation -1.72
    TCRX A TScan Therapeutics, Inc. 1.65
    NVS B Novartis AG 1.10
    ENTA D Enanta Pharmaceuticals, Inc. -1.75
    RPRX F Royalty Pharma plc 0.58
    PHAR F Pharming Group N.V. 2.40
    INCY F Incyte Corporation 0.17
    ALNY F Alnylam Pharmaceuticals, Inc. -1.55
    NTLA F Intellia Therapeutics, Inc. -1.67
    PLRX F Pliant Therapeutics, Inc. -4.95
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Biotechnology Immune System Infectious Diseases Life Sciences Medicine Pharmaceutical Solid Tumors Amyloid Amyloidosis Antitrypsin Deficiency Biology Biopharmaceutical Biopharmaceutical Products Chemical Compounds Hematologic Malignancies Immunology Liver Disease Metabolism Transthyretin Acne

    Related ETFs - A few ETFs which own one or more of the above listed Novartis stocks.

    Symbol Grade Name Weight
    FLSW C Franklin FTSE Switzerland ETF 12.27
    EWL C iShares MSCI Switzerland Capped Index Fund 11.99
    SURI D Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 7.52
    GERM F ETFMG Treatments Testing and Advancements ETF 7.19
    GNOM F Global X Genomics & Biotechnology ETF 6.52
    View all Novartis ETFs...
    Compare ETFs
    Compare FLSW to EWL Compare GERM to GNOM Compare SURI to GNOM

        Novartis Stocks Recent News

        Date Stock Title
        Apr 24 TCRX TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
        Apr 24 NVS Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript
        Apr 24 INCY Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
        Apr 24 NVS Company News for Apr 24, 2024
        Apr 24 XOMA Actym Therapeutics Appoints Thomas Smart as CEO
        Apr 24 PHAR Pharming Group to report first quarter 2024 financial results on May 8
        Apr 24 PHAR Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
        Apr 24 NVS Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
        Apr 23 NVS Why Novartis Stock Topped the Market on Tuesday
        Apr 23 NVS FDA Approves Novartis' Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
        Apr 23 INCY Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
        Apr 23 NVS Novartis wins pediatric indication for Lutathera for rare cancer
        Apr 23 XOMA Day One wins FDA nod for brain cancer therapy, Ojemda
        Apr 23 NVS Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
        Apr 23 NVS Top Midday Stories: Shares of GE, Novartis, Danaher and Philip Morris Up Post-Earnings; Pepsi Stock Down Post-Earnings; Apple iPhone China Sales Drop 19%; Trump Poised for Windfall From Media Company Stock
        Apr 23 NVS Novartis AG (NVS) Q1 2024 Earnings Call Transcript
        Apr 23 NVS Novartis Stock Jumps After Beating Expectations, Raising Guidance
        Apr 23 NVS Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
        Apr 23 NVS Novartis raises full-year guidance on Q1 beat, drug sales
        Apr 23 NVS How Novartis Rode Two Blockbuster Drugs To Its Beat And Raise, And Three-Day Sprint
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Biotechnology Immune System Infectious Diseases Life Sciences Medicine Pharmaceutical Solid Tumors Amyloid Amyloidosis Antitrypsin Deficiency Biology Biopharmaceutical Biopharmaceutical Products Chemical Compounds Hematologic Malignancies Immunology Liver Disease Metabolism Transthyretin Acne
        Novartis

        Browse All Tags